R.M.M. Hupperts

Brochet, B., Solari, A., Lechner-Scott, J., Piehl, F., Langdon, D., Hupperts, R., Selmaj, K., Patti, F., Brieva, L., Maidal, E. M., Alexandri, N., Smyk, A., Nolting, A., Montalban, X., & Kubala Havrdova, E. (2024). Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary. Neurodegenerative disease management, 14(6), 193-201. https://doi.org/10.1080/17582024.2024.2429970

Kreiter, D., Kalincik, T., Hupperts, R., Patti, F., Spitaleri, D., Foschi, M., Surcinelli, A., Maimone, D., Yamout, B., Khoury, S. J., Lechner-Scott, J., Ozakbas, S., Gerlach, O., Turkoglu, R., Soysal, A., Boz, C., Al-Asmi, A., Alkhaboori, J., Amato, M. P., ... the MSBase Study Group (2024). Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study. Cns Drugs, 38(11), 921-930. https://doi.org/10.1007/s40263-024-01115-x

Kreiter, D., Postma, A. A., Hupperts, R., & Gerlach, O. H. H. (2024). Hallmarks of spinal cord pathology in multiple sclerosis. Journal of the neurological sciences, 456(1), Article 122846. https://doi.org/10.1016/j.jns.2023.122846

Mimpen, M., Kreiter, D., Kempkens, T., Knippenberg, S., Hupperts, R., & Gerlach, O. (2024). Humoral immune response after SARS-CoV-2 vaccination in cladribine-treated multiple sclerosis patients. Vaccine: X, 16, Article 100445. https://doi.org/10.1016/j.jvacx.2024.100445

Brochet, B., Solari, A., Lechner-Scott, J., Piehl, F., Langdon, D., Hupperts, R., Selmaj, K., Patti, F., Brieva, L., Maida, E. M., Alexandri, N., Smyk, A., Nolting, A., Keller, B., Montalban, X., Kubala Havrdova, E., & The Clarify-MS Investigators (2023). Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study. Multiple Sclerosis Journal, 29(14), 1808-1818. Article 13524585231205962. https://doi.org/10.1177/13524585231205962

Kreiter, D., Spee, R., Merry, A., Hupperts, R., & Gerlach, O. H. H. (2023). Effect of disease-modifying treatment on spinal cord lesion formation in multiple sclerosis: A retrospective observational study. Multiple Sclerosis and Related Disorders, 79(1), Article 104994. https://doi.org/10.1016/j.msard.2023.104994

Giovannoni, G., Popescu, V., Wuerfel, J., Hellwig, K., Iacobeus, E., Jensen, M. B., Garcia-Dominguez, J. M., Sousa, L., De Rossi, N., Hupperts, R., Fenu, G., Bodini, B., Kuusisto, H. M., Stankoff, B., Lycke, J., Airas, L., Granziera, C., & Scalfari, A. (2022). Smouldering multiple sclerosis: the 'real MS'. Therapeutic Advances in Neurological Disorders, 15, Article 17562864211066751. https://doi.org/10.1177/17562864211066751

Brochet, B., Hupperts, R., Langdon, D., Solari, A., Piehl, F., Lechner-Scott, J., Montalban, X., Selmaj, K., Valis, M., Rejdak, K., Havrdova, E. K., Patti, F., Alexandri, N., Nolting, A., & Keller, B. (2022). Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Multiple Sclerosis and Related Disorders, 57, Article 103385. https://doi.org/10.1016/j.msard.2021.103385

Kreiter, D. J., van den Hurk, J., Wiggins, C. J., Hupperts, R. M. M., & Gerlach, O. H. H. (2022). Ultra-high field spinal cord MRI in multiple sclerosis: Where are we standing? A literature review. Multiple Sclerosis and Related Disorders, 57, Article 103436. https://doi.org/10.1016/j.msard.2021.103436

Mimpen, M., Rolf, L., Poelmans, G., van den Ouweland, J., Hupperts, R., Damoiseaux, J., & Smolders, J. (2021). Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis. PLOS ONE, 16(12), Article e0261097. https://doi.org/10.1371/journal.pone.0261097